Artelo Biosciences Inc
ARTL7.195USD
-0.060-0.85%
Handelsschluss 06/13, 16:00（ET）Kurse um 15 Minuten verzögert
23.61MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Artelo Biosciences Inc Unternehmen
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.
Unternehmensinformationen
BörsenkürzelARTL
Name des UnternehmensArtelo Biosciences Inc
IPO-datumOct 13, 2015
Gegründet am2011
CEOMr. Gregory D. (Greg) Gorgas
Anzahl der mitarbeiter6
WertpapierartOrdinary Share
GeschäftsjahresendeOct 13
Addresse505 Lomas Santa Fe, Suite 160
StadtSOLANA BEACH
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl92075
Telefon18589257049
Websitehttps://artelobio.com/
BörsenkürzelARTL
IPO-datumOct 13, 2015
Gegründet am2011
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Gregory D. (Greg) Gorgas
Mr. Gregory D. (Greg) Gorgas
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
3.41K
--
Ms. Connie L. Matsui
Ms. Connie L. Matsui
Independent Chairperson of the Board
Independent Chairperson of the Board
630.00
--
Mr. Steven (Steve) Kelly
Mr. Steven (Steve) Kelly
Independent Director
Independent Director
139.00
--
Ms. Tamara A. (Seymour) Favorito, CPA
Ms. Tamara A. (Seymour) Favorito, CPA
Independent Director
Independent Director
--
--
Dr. Gregory R. Reyes, M.D., Ph.D.
Dr. Gregory R. Reyes, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Douglas Blayney, M.D.
Dr. Douglas Blayney, M.D.
Independent Director
Independent Director
--
--
Dr. R. Martin Emanuele, Ph.D.
Dr. R. Martin Emanuele, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Gregory D. (Greg) Gorgas
Mr. Gregory D. (Greg) Gorgas
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
3.41K
--
Ms. Connie L. Matsui
Ms. Connie L. Matsui
Independent Chairperson of the Board
Independent Chairperson of the Board
630.00
--
Mr. Steven (Steve) Kelly
Mr. Steven (Steve) Kelly
Independent Director
Independent Director
139.00
--
Ms. Tamara A. (Seymour) Favorito, CPA
Ms. Tamara A. (Seymour) Favorito, CPA
Independent Director
Independent Director
--
--
Dr. Gregory R. Reyes, M.D., Ph.D.
Dr. Gregory R. Reyes, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Douglas Blayney, M.D.
Dr. Douglas Blayney, M.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, May 16
Aktualisiert: Fri, May 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Geode Capital Management, L.L.C.
0.82%
Citadel Advisors LLC
0.69%
Gorgas (Gregory D)
0.62%
Susquehanna International Group, LLP
0.62%
UBS Financial Services, Inc.
0.39%
Other
96.86%
Aktionäre
Aktionäre
Anteil
Geode Capital Management, L.L.C.
0.82%
Citadel Advisors LLC
0.69%
Gorgas (Gregory D)
0.62%
Susquehanna International Group, LLP
0.62%
UBS Financial Services, Inc.
0.39%
Other
96.86%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
1.01%
Investment Advisor/Hedge Fund
0.90%
Individual Investor
0.81%
Hedge Fund
0.81%
Other
96.46%
Institutionelle Beteiligung
Aktualisiert: Mon, Mar 3
Aktualisiert: Mon, Mar 3
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
23
63.92K
1.95%
-37.27K
2024Q4
25
63.92K
1.95%
-99.86K
2024Q3
26
51.99K
1.61%
-115.04K
2024Q2
32
55.13K
1.71%
-137.29K
2024Q1
31
54.26K
1.68%
-150.15K
2023Q4
38
55.07K
1.83%
-168.01K
2023Q3
40
80.20K
2.79%
-263.28K
2023Q2
40
67.48K
2.36%
-288.11K
2023Q1
40
75.80K
2.65%
-285.67K
2022Q4
41
142.96K
5.02%
-236.79K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Geode Capital Management, L.L.C.
17.35K
0.53%
--
--
Dec 31, 2024
Gorgas (Gregory D)
20.45K
0.62%
--
--
Feb 27, 2025
UBS Financial Services, Inc.
13.30K
0.41%
+13.30K
--
Dec 31, 2024
Tower Research Capital LLC
3.82K
0.12%
-1.36K
-26.34%
Dec 31, 2024
Matsui (Connie L)
3.78K
0.12%
--
--
Feb 27, 2025
Northern Trust Investments, Inc.
2.68K
0.08%
+2.68K
--
Dec 31, 2023
Blayney (Douglas W)
834.00
0.03%
--
--
Feb 27, 2025
Kelly (Steven)
834.00
0.03%
--
--
Feb 27, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Aug 09, 2022
Merger
15<1
Aug 09, 2022
Merger
15<1
Aug 09, 2022
Merger
15<1
Aug 09, 2022
Merger
15<1
Datum
Art
Verhältnis
Aug 09, 2022
Merger
15<1
Aug 09, 2022
Merger
15<1
Aug 09, 2022
Merger
15<1
Aug 09, 2022
Merger
15<1
